![Carolyn F. Sidor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Carolyn F.
Sidor served as the Chief Medical Officer & Vice President at CASI Pharmaceuticals, Inc. from 2001 to 2012.
She then worked as the Chief Medical Officer & Senior Vice President at Kolltan Pharmaceuticals, Inc. from 2013 to 2014.
Prior to that, she was the Vice President-Scientific & Medical Development at Cato Research LLC.
Sidor holds a doctorate from Thomas Jefferson University, an undergraduate degree from SUNY College of Environmental Science, and an MBA from the University of Delaware.
Former positions of Carolyn F. Sidor
Companies | Position | End |
---|---|---|
CASI Pharmaceuticals, Inc. /Old/
![]() CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Chief Tech/Sci/R&D Officer | 2012-05-22 |
Kolltan Pharmaceuticals, Inc.
![]() Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | - |
Cato Research LLC
![]() Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
Training of Carolyn F. Sidor
Thomas Jefferson University | Doctorate Degree |
University of Delaware | Masters Business Admin |
SUNY College of Environmental Science | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
CASI Pharmaceuticals, Inc. /Old/
![]() CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Health Technology |
Cato Research LLC
![]() Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Commercial Services |
Kolltan Pharmaceuticals, Inc.
![]() Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
- Stock Market
- Insiders
- Carolyn F. Sidor